Evidence map›Paper›PMID 36010289›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Detection of Anti-Vimentin Antibodies in Patients with Sarcoidosis.

Anna Starshinova, Anna Malkova, Ulia Zinchenko, Sergey Lapin, Alexandra Mazing, Dmitry Kudlay, Piotr Yablonskiy, Yehuda Shoenfeld

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Immunopathogenesis of Sarcoidosis.Seminars in respiratory and critical care medicine · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Anna StarshinovaLaboratory of the Mosaic of Autoimmunity, Medical Department, St. Petersburg State University, 199034 St. Petersburg, Russia.ORCID 0000-0002-9023-6986
Anna MalkovaLaboratory of the Mosaic of Autoimmunity, Medical Department, St. Petersburg State University, 199034 St. Petersburg, Russia.ORCID 0000-0002-6008-1354
Ulia ZinchenkoLaboratory of the Mosaic of Autoimmunity, Medical Department, St. Petersburg State University, 199034 St. Petersburg, Russia.ORCID 0000-0002-6273-4304
Sergey LapinLaboratory for the Diagnosis of Autoimmune Diseases of the Scientific and Methodological Center, St. Petersburg State Medical University, 194100 St. Petersburg, Russia.ORCID 0000-0002-4998-3699
Alexandra MazingLaboratory for the Diagnosis of Autoimmune Diseases of the Scientific and Methodological Center, St. Petersburg State Medical University, 194100 St. Petersburg, Russia.ORCID 0000-0002-3055-6507
Dmitry KudlayDepartment of Pharmacology, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia.ORCID 0000-0003-1878-4467
Piotr YablonskiyLaboratory of the Mosaic of Autoimmunity, Medical Department, St. Petersburg State University, 199034 St. Petersburg, Russia.
Yehuda ShoenfeldLaboratory of the Mosaic of Autoimmunity, Medical Department, St. Petersburg State University, 199034 St. Petersburg, Russia.
St Petersburg University · RUSaint Petersburg State Pediatric Medical University · RUSechenov University · RUTel Aviv University · IL

Funding

by Grant from the Government of the Russian Federation 14W03.31.0009
6 · The paper itself

Abstract

There is a need to further characterize the antibody response to vimentin in relation to its possible involvement in pathogenicity of sarcoidosis and other lung disorders.

objectivesWe investigated serum samples from patients with sarcoidosis, healthy controls and controls with other non-infectious lung diseases., to evaluate levels and frequency of these antibodies. MATERIALS AND

methodsA retrospective-prospective comparative study was performed in the years 2015-2019. Sera from 93 patients with sarcoidosis, 55 patients with non-infectious lung diseases and 40 healthy subjects was examined for presence of autoantibodies to mutated citrullinated vimentin (anti-MCV). Patients with elevated anti-MCV levels were tested for antibodies to a cyclic citrullinated peptide (anti-CCP) and citrullinated vimentin (anti-Sa). In all cases ELISA assays was used. The results were considered statistically significant at RESULTS OF THE STUDY: The high concentrations of anti-MCV antibodies were more frequent in patients with sarcoidosis (40.9% of the cases, 38/93), compared to the control groups (23.6% and 25.0% of cases, respectively). In sarcoidosis, clinical symptoms similar to the autoimmune pathology were described. A moderate positive correlation between the anti-MCV and anti-Sa antibodies (r = 0.66) was found in 13 patients with sarcoidosis. There was no significant difference between the levels of the anti-MCV and the anti-CCP in patients with non-infectious lung diseases and the healthy control group.

conclusionAntibodies to citrullinated cyclic peptides are not significant in the pathogenesis of sarcoidosis and other investigated pulmonary diseases (COPD, granulomatosis with polyangiitis, alveolitis) and based on their low concentration, it can be assumed that citrullination and modification of vimentin is not a key factor in the development of an autoimmune response in patients with sarcoidosis.

Indexed as

autoantibodiesautoimmunitygranulomatous diseasesmutated vimentinsarcoidosisvimentin

Identifiers

PMID36010289
PMCPMC9406612
OpenAlexW4291016724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.